E

Blueprint Shows Promise in GIST and HCC

Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...

February 16, 2017
E

How to improve response rates with targeted therapies in oncology

Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches

February 2, 2017
E

A manifesto for immuno-oncology research

A draft manifesto for IO in cancer research and what we need to learn

February 1, 2017
E

ASH16 Update on BCMA CAR T cell therapies

A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma

December 14, 2016
E

Gems from the Poster Halls at EORTC-NCI-AACR in Munich

Gems from the Poster Hall on Wednesday at EORTC-NCI-AACR Molecular Targets meeting in Munich

November 30, 2016
E

Making breast cancer cells become normal again

Can we revert the mutant phenotype in breast cancer and return to a normal, non cancerous phenotype?

November 30, 2016
E

ENA 2016 Immunotherapy Symposium Highlights

Highlights from the Charles River Immunotherapy Symposium in Munich, 2016

November 29, 2016